More countries must provide the right incentives to develop drugs to combat antibiotic resistance. The FT's Andrew Jack explores the trend to tackle a growing global health threat by de-linking incentive payments to pharmaceutical companies from sales, offering pharma companies guaranteed income for innovative treatments
See if you get the FT for free as a student (http://ft.com/schoolsarefree) or start a £1 trial: https://subs.ft.com/spa3_trial?segmentId=3d4ba81b-96bb-cef0-9ece-29efd6ef2132

► Check out our Community tab for more stories or to suggest videos.
► Listen to our podcasts: https://www.ft.com/podcasts
► Follow us on Instagram: https://www.instagram.com/financialtimes